You are here

WJ-MSC-secreted Fibulin-5 Attenuates PNS Myelination

As no effective treatments for the demyelinating disease Charcot‐Marie‐Tooth (CMT) have been developed to date, researchers led by Jong Wook Chang (Samsung Medical Center) and Ji Eun Lee (Sungkyunkwan University, Seoul, South Korea) sought to explore the potential of mesenchymal stem cell‐based therapies. In their recent STEM CELLS article, Won et al. now suggest human Wharton's jelly‐derived mesenchymal stem cells (WJ‐MSCs) or Fibulin-5, a critical paracrine acting factor, as a treatment option for CMT by restoring the myelination defects of Schwann cells.